The Litigator

THE LITIGATOR

Commentary on Law Affecting Business

The Litigator
AGM :: Affleck Greene McMurtry LLP

THE LITIGATOR

Affleck Greene McMurtry LLP
365 Bay Street, Suite 200  ·  Toronto, Canada
416 360 2800  ·  info@agmlawyers.com  ·  www.thelitigator.ca

Bureau Remedies Allergan Acquisition

iStock_000015181498_Full

An asset sale a day keeps the Bureau at bay

In a consent agreement reached with the Competition Bureau, has agreed to divest assets related to two pharmaceutical products in order to complete its acquisition of in Canada.

Following its review of the proposed transaction, the Bureau concluded that it would likely have resulted in a substantial lessening or prevention of competition for the supply of

  • tobramycin inhalation solution (used for the management of cystic fibrosis in patients with certain chronic pulmonary infections); and
  • buprenorphine/naloxone oral tablets (used for substitution treatment in adult opioid drug dependence).

Under the consent agreement, the Commissioner has sole discretion to approve one or more buyers of the products, provided that the proposed buyer will provide effective competition in Canada.

Read the full press release from the Competition Bureau here.

Daphne Hooper
Affleck Greene McMurtry LLP

Daphne Hooper

Daphne represents clients in a broad range of commercial matters and is a valued member of the firm’s competition law practice group. Her experience includes complex contractual disputes, multi-jurisdictional class actions, employment matters and professional negligence, including errors and omissions by brokers/dealers and lawyers.

Contributor's Archive

Contributor's Profile